Salute e Benessere
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
" says Anna Ljung , CEO of Moberg Pharma.
says Christoffer Lorenzen , CEO of Karo.
Terbinafine, originally developed and launched by Novartis under the Lamisil® brand, has long been considered the gold standard treatment for skin and foot fungal infections such as athlete's foot and nail fungus. Lamisil® is present in more than 60 markets worldwide and has become synonymous with its active ingredient, terbinafine, while consistently standing at the forefront of antifungal research and innovation.
MOB-015/Terclara®, developed by Moberg Pharma, represents the next generation of terbinafine therapy – a new topical formulation. Oral treatment of nail fungus is associated with risks such as interactions with other medications and liver damage, which are avoided with topical treatment. Previous attempts at topical treatment with terbinafine have failed due to the difficulty of delivering a sufficient amount of the active substance through the nail. MOB-015 is the first topical treatment that has achieved mycological cure on par with oral treatment, with 76% of patients achieving mycological cure in the registration studies. It is therefore particularly satisfying to launch the product under the strong and fitting Lamisil® brand.
Launching MOB-015/Terclara® under the Lamisil® brand, wherever possible, optimizes the product's chances to take a leading position in major European markets. However, the use of the Lamisil® brand for this pharmaceutical product requires approval by the respective national health authorities, which affects the timing of the launch. Both companies intend to initiate launch as soon as possible.
The companies will also collaborate to expand current marketing authorizations to additional countries as soon as feasible. For regulatory reasons, markets that are already approved have priority, since new countries cannot be added while a name change or other changes are being implemented.
Although the product will be launched under the Lamisil® brand, the connection to Moberg Pharma will be made clear through the marketing concept 'Powered by Terclara®'.
Karo Healthcare is a leading European consumer healthcare company, backed by KKR, a leading global investment firm, and with ambitious growth plans across
Europe . With established distribution in all major European pharmacy chains, Karo has the capacity to manage both prescription and over-the-counter products, including prescription-to-nonprescription (Rx-to-OTC) switches.
Through this partnership with Karo Healthcare, the product gains broad market coverage and effective distribution right from the outset, which would take Moberg Pharma time to build up on its own. While Moberg Pharma will not launch Terclara® on its own in Europe as part of this collaboration, the company still plans to play an active commercial role in other territories, particularly in the U.S., as part of its long-term strategy.
The agreement marks an important milestone in Moberg Pharma's commercial expansion and lays the foundation to establish MOB-015/Terclara® as the new market leader in the treatment of nail fungus across Europe .
Moberg Pharma is releasing this information in accordance with the EU's Market Abuse Regulation (MAR). The information was released for public distribution through the contact named below at
8.30 a.m. CET on November 5th, 2025 .
Anna Ljung , CEO, Phone: +46 8 522 307 01, E-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/moberg-pharma/r/moberg-pharma-and-karo-healthcare-enter-exclusive-license-agreement-for-mob-015-terclara-in-europe--,c4261942
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/moberg-pharma-and-karo-healthcare-enter-into-an-exclusive-license-agreement-for-mob-015terclara-in-europe-expanding-access-and-growth-potential-302605302.html